2019 American Transplant Congress
Whole-Exome Sequencing Identifies PMS1 and DYRK1A Genes Contributing to Occurrence of Liver Cancer
Tongji hospital, Huazhong university, Organ Transplantation, Wuhan, China
*Purpose: Liver cancer is one of the most frequent cancers in China and the accurate landscape of liver cancer, especially of HBV-infected liver cancer in…2019 American Transplant Congress
Clinical Outcomes of Patients with Portal Vein Tumor Thrombi after Living Donor Liver Transplantation
Surgery, Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Korea, Republic of
*Purpose: Patient selection criteria for living donor liver transplantation(LDLT) with hepatocellular carcinoma are generally wider than those for deceased donor liver transplantation. It is widely…2018 American Transplant Congress
Cost Analysis of Loco-Regional Bridging Therapy for Hepatocellular Carcinoma: A National Study
Liver transplantation (LT) is cost-effective in the primary treatment of Hepatocellular carcinoma (HCC). Loco-regional therapies (LRTs) have increased as both primary therapy for HCC as…2018 American Transplant Congress
ABO‐incompatible Deceased Donor Liver Transplantation
ABO-incompatible liver transplantation (ILT) has increased over the past decade despite reports suggesting that adult ILT recipient have worse outcomes than ABO-compatible liver transplant (CLT)…2018 American Transplant Congress
Prognostic Value and Biological Significances of Five Long Non-Coding RNAs in Hepatocellular Carcinoma
Objectives Increasing evidence suggests that long non-coding RNA (lncRNA) plays a vital role in metastasis and development in hepatocellular carcinoma (HCC). Tumor progression severely affect…2018 American Transplant Congress
Small-for-Size Grafts Increase Recurrence of Hepatocellular Carcinoma in Liver Transplantation beyond Milan Criteria
Center for Liver Cancer, National Cancer Center, Goyang, Korea.
BACKGROUND: Living donor liver transplantation (LDLT) has been reported to have high rates of hepatocellular carcinoma (HCC) recurrence compared to deceased donor liver transplant (DDLT).…2018 American Transplant Congress
TP53 Mutations Lead to Increased Transcription of Circular RNAs in Exosomes Enhancing Tumor Invasiveness in Hepatocellular Carcinoma Bases on Bioinformatics Analysis
The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.
Objective Increasing evidence suggests that cicular RNAs play an important role in tumor. A recent study found the enrichment of cicular RNAs in HCC derived…2018 American Transplant Congress
Impact of Donor Age on Outcomes after Living Donor Liver Transplantation
Background: Liver transplantation (LT) is a curative treatment for decompensated cirrhosis and fulminant hepatitis. Although not a few patients received LT with marginal donor livers…2018 American Transplant Congress
Validating MORAL in Living Donor Liver Transplantation for Hepatocellular Carcinoma
The “Model of Recurrence after Liver Transplant” (MORAL) study has identified certain pre and post operative variables that have significant impact on recurrence free survival…2018 American Transplant Congress
Living Donor Liver Transplantation for Hepatocellular Carcinoma beyond UCSF Criteria: Can We Achieve a Modest Long-Term Survival? A Single Center Retrospective Analysis of Using Extended Criteria
Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan.
Milan's criteria were universally validated for LT in HCC patients and, were accepted as allocation criteria of UNOS in 2001 & Eurotransplantation in 2006. However,…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 23
- Next Page »